Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells
Joanna S. Kritikou, … , Jordan S. Orange, Lisa S. Westerberg
Joanna S. Kritikou, … , Jordan S. Orange, Lisa S. Westerberg
Published February 23, 2021
Citation Information: JCI Insight. 2021;6(6):e140273. https://doi.org/10.1172/jci.insight.140273.
View: Text | PDF
Research Article Immunology

Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells

  • Text
  • PDF
Abstract

X-linked neutropenia (XLN) is caused by gain-of-function mutations in the actin regulator Wiskott-Aldrich Syndrome protein (WASp). XLN patients have reduced numbers of cytotoxic cells in peripheral blood; however, their capacity to kill tumor cells remains to be determined. Here, we examined NK and T cells from 2 patients with XLN harboring the activating WASpL270P mutation. XLN patient NK and T cells had increased granzyme B content and elevated degranulation and IFN-γ production when compared with healthy control cells. Murine WASpL272P NK and T cells formed stable synapses with YAC-1 tumor cells and anti-CD3/CD28–coated beads, respectively. WASpL272P mouse T cells had normal degranulation and cytokine response whereas WASpL272P NK cells showed an enhanced response. Imaging experiments revealed that while WASpL272P CD8+ T cells had increased accumulation of actin upon TCR activation, WASpL272P NK cells had normal actin accumulation at lytic synapses triggered through NKp46 signaling but had impaired response to lymphocyte function associated antigen-1 engagement. When compared with WT mice, WASpL272P mice showed reduced growth of B16 melanoma and increased capacity to reject MHC class I–deficient cells. Together, our data suggest that cytotoxic cells with constitutively active WASp have an increased capacity to respond to and kill tumor cells.

Authors

Joanna S. Kritikou, Mariana M.S. Oliveira, Julien Record, Mezida B. Saeed, Saket M. Nigam, Minghui He, Marton Keszei, Arnika K. Wagner, Hanna Brauner, Anton Sendel, Saikiran K. Sedimbi, Stamatina Rentouli, David P. Lane, Scott B. Snapper, Klas Kärre, Peter Vandenberghe, Jordan S. Orange, Lisa S. Westerberg

×

Figure 5

NK and CD8+ T cells from WASpL272P mice have a different spreading and F-actin polarizing response on coated glass.

Options: View larger image (or click on image) Download as PowerPoint
NK and CD8+ T cells from WASpL272P mice have a different spreading and F...
(A and B) Confocal images of WASp-KO, WT, and WASpL272P (A) NK cells and (B) CD8+ T cells to assess attachment and F-actin density toward the indicated coated surface. Representative images are shown (left) and graphs quantifying the attachment area (top right) and F-actin density by confocal imaging (bottom right) in arbitrary units. Images are displayed as inverted gray scale Lookup Table of phalloidin staining. Two individual experiments combined are shown. Each dot represents 1 cell. For each condition, between 200 and 400 cells were analyzed. Graphs show mean values ± SEM and significance was assessed by 1-way ANOVA. *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001.

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts